Eduardo Garcia
Cardiovascular Disease · Dearborn, MINPI 1730149451
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $602 and has fallen 96.5% since, to $21 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in MI, where the typical reported total is $2,775.
Across 76 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$269
- Sanofi-aventis U.S. LLC$127
- AstraZeneca$116
- Johnson & Johnson$98
- Boehringer Ingelheim$89
- Boston Scientific$70
- plus $460 from 15 others
What the payments were for
- Food & beverage$1,228100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 20 | $269 |
| Sanofi-aventis U.S. LLC | 6 | $127 |
| AstraZeneca | 8 | $116 |
| Johnson & Johnson | 6 | $98 |
| Boehringer Ingelheim | 5 | $89 |
| Boston Scientific | 4 | $70 |
| Pfizer | 4 | $60 |
| United Therapeutics Corporation | 3 | $56 |
| Daiichi Sankyo Inc. | 2 | $49 |
| Actelion Pharmaceuticals US, Inc. | 2 | $45 |
| Amgen | 2 | $37 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $34 |
| Preventice Services, LLC | 2 | $31 |
| Edwards Lifesciences | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $28 |
| Exeltis, USA Inc. | 1 | $22 |
| Abbott | 1 | $16 |
| Gilead | 1 | $14 |
| Novo Nordisk | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
How this compares
$1,228 in reported general payments places this provider in the 35th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Dearborn
- Elias KassabDearborn$172K
- Sohail HassanDearborn$121K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.